Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GP-82996 (CINK4) (CINK4) 是 CDK4/6的药理学抑制剂。GP-82996 对 CDK4/cyclin D1、CDK6/cyclin D1 和 Cdk5/p35 的 IC50s 分别为 1.5、5.6 和 25 μM。GP-82996 诱导肿瘤细胞 U2OS 的凋亡,可用于癌症研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 333 | 现货 | ||
5 mg | ¥ 797 | 现货 | ||
10 mg | ¥ 1,260 | 现货 | ||
25 mg | ¥ 2,580 | 现货 | ||
50 mg | ¥ 4,120 | 现货 | ||
100 mg | ¥ 6,150 | 现货 |
产品描述 | GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2]. |
体外活性 | GP-82996 (5, 10 μM; 24 hours) induces G1 arrest and G0-G1/S ratio increase in U2OS (p16 negative) and MRC-5 (p16 positive) cells [1]. GP-82996 (5, 10 μM; 24 hours) reduces hyperphosphorylation of pRb, but has no effect on CDK4 levels in U2OS, MRC-5 cells [1]. GP-82996 (5, 10 μM; 48 hours) induces aooptosis in 83% of U2OS cells in concentration of 10μM [1]. GP-82996 (0.1-40 μM; 24,48, 72 hours) inhibits the cell proliferation of A549, H358, SKLU-1, H23, PC14 cells with IC 50 values of 72 h are 4-7 μM [2]. GP-82996 (3, 5, 10 μM; 48 hours) induces G1 arrest in A549 and H23 cells [2]. GP-82996 ((1, 3, 5, 10 μM; 72 hours) enhances Paclitaxel sensitivity in KRAS mutation-bearing lung cancer cells (A549, SKLU-1, H23 cells) [2]. GP-82996 (10 μM; 72 hours) combined with Paclitaxel (3 nM; 72 hours) increases the apoptosis of A549 and H23 cells [2]. |
体内活性 | GP-82996 (30 mg/kg, i.p. for 29 days) exhibits smaller final tumor volume compared with vehicle control in mouse xenograft models [1]. Animal Model: 19-21 g female BALB/c nu/nu mice xenograft model (HCT116 tumors volume=100 mm 3 ) [1] Dosage: 30 mg/kg Administration: i.p. every 12 hours for 29 days Result: Showed smaller final tumor volume compared with vehicle control in mouse xenograft models. |
别名 | Cdk4/6 Inhibitor IV, CINK4 |
分子量 | 456.58 |
分子式 | C27H32N6O |
CAS No. | 359886-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27mg/mL (59.1mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1902 mL | 10.951 mL | 21.902 mL | 54.7549 mL |
5 mM | 0.438 mL | 2.1902 mL | 4.3804 mL | 10.951 mL | |
10 mM | 0.219 mL | 1.0951 mL | 2.1902 mL | 5.4755 mL | |
20 mM | 0.1095 mL | 0.5475 mL | 1.0951 mL | 2.7377 mL | |
50 mM | 0.0438 mL | 0.219 mL | 0.438 mL | 1.0951 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GP-82996 359886-84-3 Cell Cycle/Checkpoint CDK GP82996 CINK-4 Cdk4/6 Inhibitor IV CINK4 GP 82996 CINK 4 Inhibitor inhibitor inhibit